Literature DB >> 20839381

Prostate cancer. Immunotherapy and combined chemotherapy for castration-resistant and metastatic disease.

Nick Groves-Kirkby.   

Abstract

Entities:  

Year:  2010        PMID： 20839381     DOI： 10.1038/nrurol.2010.124

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.

Authors:  Trine Zeeberg Buch-Hansen; Lise Bentzen; Steinbjoern Hansen; Morten Hoeyer; Niels Viggo Jensen; Charlotte Saxe; Lisa Sengeloev
Journal:  Cancer Chemother Pharmacol       Date:  2009-10-31       Impact factor: 3.333

2.  A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.

Authors:  Masanori Noguchi; Tatsuyuki Kakuma; Hirotsugu Uemura; Yasutomo Nasu; Hiromi Kumon; Yasuhiko Hirao; Fukuko Moriya; Shigetaka Suekane; Kei Matsuoka; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh
Journal:  Cancer Immunol Immunother       Date:  2010-02-10       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.